MannKind Co. (NASDAQ:MNKD) Holdings Lifted by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC raised its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 37.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,304,085 shares of the biopharmaceutical company's stock after acquiring an additional 894,486 shares during the quarter. MannKind makes up approximately 2.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 8th largest position. Parkman Healthcare Partners LLC owned 1.20% of MannKind worth $20,783,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Millennium Management LLC raised its holdings in MannKind by 189.8% in the 2nd quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company's stock valued at $24,766,000 after buying an additional 3,107,598 shares during the last quarter. TSP Capital Management Group LLC increased its position in MannKind by 196.0% during the 2nd quarter. TSP Capital Management Group LLC now owns 2,391,900 shares of the biopharmaceutical company's stock valued at $12,486,000 after purchasing an additional 1,583,800 shares during the period. Charles Schwab Investment Management Inc. increased its position in MannKind by 1.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,224,829 shares of the biopharmaceutical company's stock valued at $13,994,000 after purchasing an additional 42,041 shares during the period. 180 Wealth Advisors LLC increased its position in MannKind by 4.7% during the 2nd quarter. 180 Wealth Advisors LLC now owns 2,034,134 shares of the biopharmaceutical company's stock valued at $11,411,000 after purchasing an additional 91,924 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in MannKind during the 3rd quarter valued at approximately $12,252,000. Institutional investors own 49.55% of the company's stock.

MannKind Trading Up 1.3 %

NASDAQ MNKD traded up $0.09 during mid-day trading on Wednesday, hitting $6.80. The company's stock had a trading volume of 2,776,899 shares, compared to its average volume of 2,647,490. The company's 50 day simple moving average is $6.72 and its 200 day simple moving average is $5.88. MannKind Co. has a twelve month low of $3.17 and a twelve month high of $7.63. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 95.86 and a beta of 1.28.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Leerink Partnrs raised shares of MannKind to a "strong-buy" rating in a research report on Monday, September 9th. Oppenheimer increased their target price on shares of MannKind from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Wednesday, August 28th. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a research report on Friday, November 29th. Finally, Leerink Partners started coverage on shares of MannKind in a research report on Monday, September 9th. They set an "outperform" rating and a $8.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, MannKind currently has a consensus rating of "Buy" and a consensus price target of $8.67.

Insider Activity at MannKind

In other MannKind news, Director Steven B. Binder sold 67,539 shares of the company's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $6.76, for a total value of $456,563.64. Following the completion of the sale, the director now directly owns 1,075,026 shares of the company's stock, valued at approximately $7,267,175.76. This represents a 5.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Stuart A. Tross sold 55,000 shares of MannKind stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the transaction, the insider now directly owns 967,191 shares in the company, valued at approximately $7,099,181.94. This represents a 5.38 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is owned by company insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.